Related Experiment Video
Updated: Mar 26, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma
Nabila Bennani-Baiti1, Gita Thanarajasingam1, Stephen Ansell1
1a Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Abstract:
Hodgkin lymphoma's (HL) tumor composition is characterized by a paucity of malignant cells and a preponderance of immune and stromal cells. Despite the rich immune milieu within the tumor microenvironment, malignant cells are able to effectively evade the immune system and use immune support to promote lymphoma cell growth and proliferation. Recognizing this has led to the identification of checkpoint inhibitory signals that enable immune evasion and to opening the door to therapeutic strategies on how to exploit the immune system in targeting tumor cells. We discuss herein some of the tumor evasion mechanisms in HL with a particular focus on the immune checkpoint pathways and focus on recent clinical data of checkpoint blockade in HL treatment.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Inhibitors of Viral Protein Synthesis
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy

